Skip to main content
All lobbying filings

CAPITOL COUNSEL LLC

Lobbying for CMC PHARMACEUTICALS · Developing new and better drug formulations.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · Ohio · House · Senate · $40,000.00 income · posted Jul 17, 2026

Official filing document

 Bills named in this filing 2
  • HR 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S 4784
    National Defense Authorization Act for Fiscal Year 2027
 Lobbying activity 3
Budget/Appropriations

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection funding.

Defense

Issues related to the FY27 National Defense Authorization Act (H.R. 8800/ S. 4784) and Defense Appropriations.

Government Issues

Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem